World Health Organization

20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT

Prequalification Unit Inspection services
WHO PUBLIC INSPECTION REPORT

Desk Assessment of Finished Product Manufacturer

Part 1	**General information**
Company information	
Name of Manufacturer	Cipla Ltd, Patalganga Unit I (FPP)
Name of Manufacturer	Cipla Ltd, Patalganga Unit II (FPP)
Corporate address of manufacturer	Cipla House, Peninsula Business Park, Ganpatrao Kadam, Marg, Lower Parel, Mumbai 400013, India
Inspected site	
Name & address of manufacturing site	Cipla Ltd, **Unit I** (FPP) Plot A-33, A37/2/2 & A-2 M.I.D.C., Patalganga, Taluka: Khalapur, District: Raigad Maharashtra state, 410 220, India. D-U-N-S: 916940208 Latitude: 18°, 877177`N Longitude: 73°, 182783`E
Production Block/Unit	Unit I
Manufacturing license number	License No (25) 845 & (28) 707 valid until 31.12.2022
Name & address of manufacturing site	Cipla Ltd, U**nit II** (FPP) Plot A-42 M.I.D.C., Patalganga, Taluka: Khalapur, District: Raigad Maharashtra state, 410 220 India. D-U-N-S: 916940208 Latitude: 18°, 875662`N Longitude: 73°, 178696`E
Production Block/Unit	Unit II
Manufacturing license number	Form 26 - license No (25) KD620 & (28) KD 435 valid until 17.08.2021
Desk assessment details	
Start and end dates of review	12 – 23 October 2020
Inspection record number	Unit I INSP-2018-0088
Products covered by this desk assessment Unit I	Abacavir (sulfate)/Lamivudine Tablet USP 600mg/300mg Abacavir (sulfate) Tablet 300mg Abacavir (sulfate) Tablet, Dispersible 60mg Abacavir (sulfate)/Lamivudine Tablet, Dispersible 60mg/30mg Isoniazid/Pyridoxine hydrochloride/Sulfamethoxazole/Trimethoprim Tablet 300mg/25mg/800mg/160mg Abacavir (sulfate)/Lamivudine Tablet, Dispersible 120mg/60mg Artemether/Lumefantrine Tablet 20mg/120mg

	Amodiaquine (hydrochloride)/Artesunate Tablet 67.5mg/25mg	
	Amodiaquine (hydrochloride)/Artesunate Tablet 135mg/50mg	
	Amodiaquine (hydrochloride)/Artesunate Tablet 270mg/100mg	
	Abacavir (sulfate)/Lamivudine Tablet, Film-coated 600mg/300mg	
Products covered by this desk assessment Unit II	Abacavir (sulfate) Tablet 300mg	
	Nevirapine Tablet, Dispersible 50mg	
	Nevirapine Tablet, Dispersible 100mg	
	Abacavir (sulfate)/Lamivudine Tablet, Dispersible 60mg/30mg	
	Efavirenz/Lamivudine/Tenofovir disoproxil fumarate Tablet, Film-coated 600mg/300mg/300mg	
	Darunavir (Ethanolate) Tablet, Film-coated 400mg	
	Darunavir (Ethanolate) Tablet, Film-coated 600mg	
	Atazanavir (sulfate)/Ritonavir Tablet, Film-coated 300mg/100mg	
	Isoniazid/Pyridoxine hydrochloride/Sulfamethoxazole/Trimethoprim Tablet 300mg/25mg/800mg/160mg	
	Abacavir (sulfate)/Lamivudine Tablet, Dispersible 120mg/60mg	
	Darunavir (Ethanolate) Tablet, Film-coated 800mg	
	Lamivudine/Tenofovir disoproxil fumarate Tablet, Film-coated 300mg/300mg	
	Sofosbuvir Tablet, Film-coated 400mg	
	Daclatasvir (dihydrochloride) Tablet, Film-coated 30mg	
	Daclatasvir (dihydrochloride) Tablet, Film-coated 60mg	
	Daclatasvir (dihydrochloride) + Sofosbuvir Tablet, Film-coated 60mg + 400mg	
	Artemether/Lumefantrine Tablet 20mg/120mg	
	Artesunate/Mefloquine (hydrochloride) Tablet 25mg/50mg	
	Artesunate/Mefloquine (hydrochloride) Tablet 100mg/200mg	
	Amodiaquine (hydrochloride)/Artesunate Tablet 67.5mg/25mg	
	Amodiaquine (hydrochloride)/Artesunate Tablet 135mg/50mg	
	Amodiaquine (hydrochloride)/Artesunate Tablet 270mg/100mg	
	Ethionamide Tablet, Film-coated 250mg	
	Ofloxacin Tablet, Film-coated 200mg	
	Ofloxacin Tablet, Film-coated 400mg	
	Ritonavir Tablet, Film-coated 25mg	

List of documents submitted	1. USFDA EIR, dates of inspection 4 – 13 November 2019 and EIR cover letter 2. USFDA Form 483, dates of inspection 4 – 13 November 2019 3. Compliance report (CAPA) FDA inspection 4 – 13 November 2019 4. MHRA inspection report, dates of inspection 19 – 23 February 2018 5. Compliance report (CAPA) MHRA inspection, dates of inspection 19 – 23 February 2018 6. MHRA GMP certificate Unit I 7. MHRA GMP certificate Unit II 8. USFDA EIR dates of inspection 27 November – 6 December 2017 and EIR cover letter 9. USFDA Form 483, dates of inspection 27 November – 6 December 2017 10. Compliance report (CAPA) FDA inspection 27 November – 6 December 2017 11. GMP certificates Unit I (issued 19 December 2018 No NEW-WHO-GMP / CERT / KD / 73115 / 2018/ 11/ 26155, valid till 16 December 2021) and Unit II (issued 3 October 2019 No NEW-WHO

	GMP / CERT / KD / 83192 / 2019 / 11 / 29628, valid till 26 September 2022) 12. Manufacturing license Unit I issued by Food & Drugs Administration (Maharashtra State) No 28/707, issued 06/01/2018, valid till 31/12/2022 and No 25-845, issued 08/01/2018, valid till 31/12/2022 13. Manufacturing license Unit II issued by Food & Drugs Administration (Maharashtra State) No 25-KD/620, valid till 17/08/2021 and additional product permissions, No 28-KD/435, valid till 17/08/2021 14. SMF Unit I and Unit II and layouts 15. Product list Unit I and Unit II 16. A list of regulatory Inspections performed in the last 5 years and their outcomes Unit I and Unit II 17. Recall lists Unit I and Unit II 18. Confirmation self-inspection Unit I and Unit II 19. Confirmation out-of-stock situations Unit I and Unit II 20. Manufacturing process covered by SRA Unit I and Unit II 21. Unit I: completed batch manufacturing and packaging records, including the analytical part, for the most recently released batch of relevant products: a. Abacavir (sulfate)/Lamivudine Tablet USP 600mg/300mg b. Abacavir (sulfate)/Lamivudine Tablet, Dispersible 60mg/30mg c. Isoniazid/Pyridoxine hydrochloride/Sulfamethoxazole/Trimethoprim Tablet 300mg/25mg/800mg/160mg d. Abacavir (as sulfate) and Lamivudine dispersible tablets 120mg/60mg e. Abacavir (sulfate)/Lamivudine Tablet, Film-coated 600mg/300mg (HA743) 22. PQRs Unit I a. Abacavir (sulfate)/Lamivudine Tablet USP 600mg/300mg Mar 2019 – Mar 2020 b. Abacavir (sulfate) Tablet 300mg Dec 2018 – Nov 2019 c. Abacavir (sulfate) Tablet, Dispersible 60mg March 2019 – March 2020 d. Abacavir (sulfate)/Lamivudine Tablet, Dispersible 60mg/30mg May 2019- May 2020 e. Isoniazid/Pyridoxine hydrochloride/Sulfamethoxazole/Trimethoprim Tablet 300mg/25mg/800mg/160mg Sept 2018 - Aug 2019 f. Abacavir (as sulfate) and Lamivudine dispersible tablets 120mg/60mg Apr. 2019 – Apr. 2020 g. Artemether/Lumefantrine Tablet 20mg/120 mg May 2019 – Apr 2020 h. Abacavir (sulfate)/Lamivudine Tablet, Film-coated 600mg/300mg Mar 2019 – Feb 2020 23. Unit II completed batch manufacturing and packaging records, including the analytical part, for the most recently released batch of relevant products: a. Abacavir (sulfate)/Lamivudine Tablet, Dispersible 120mg/60mg b. Lamivudine/Tenofovir disoproxil fumarate Tablet, Film-coated 300mg/300mg c. Artesunate/Mefloquine (hydrochloride) Tablet 100mg/ 200mg d. Amodiaquine (hydrochloride)/Artesunate Tablet 67.5mg/25mg e. Amodiaquine (hydrochloride)/Artesunate Tablet 135mg/50mg

	f. Amodiaquine (hydrochloride)/Artesunate Tablet 270mg/100mg g. Artesunate/Mefloquine (hydrochloride) Tablet 25mg/50mg – BMR & BPR 24. PQRs Unit II a. Nevirapine Tablet, Dispersible 50mg Nov 2018 – Oct 2019 b. Abacavir (sulfate)/Lamivudine Tablet, Dispersible 60mg/30mg Feb 2018 – Jan 2019 c. Efavirenz/Lamivudine/Tenofovir disoproxil fumarate Tablet, Film-coated 600mg/300mg/300mg Nov 2017 – Oct 2018 d. Lamivudine/Tenofovir disoproxil fumarate Tablet, Film-coated 300mg/300mg Mar 2018 – Feb 2019 e. Artesunate/Mefloquine (hydrochloride) Tablet 25mg/50mg and Artesunate/Mefloquine (hydrochloride) Tablet 100 mg/200 mg Nov 2018 – Oct 2019, f. Amodiaquine (hydrochloride)/Artesunate Tablet 67.5mg/25mg, Amodiaquine (hydrochloride)/Artesunate Tablet 135mg/50mg and Amodiaquine (hydrochloride)/Artesunate Tablet 270mg/100mg Apr 2018 – Mar 2019

Any documents missing?	N/A	
Part 2	**Summary of SRA/NRA inspection evidence considered and comments**	
US FDA, USA	Dates of inspection:	4 – 13 November 2019
	Type of inspection:	Pre-announce surveillance cGMP inspection
	Block/Unit:	Unit I FPPs and APIs Unit II FPPs and APIs
	Type of products/Dosage forms covered:	• Abacavir Sulfate tablets USP 300 mg • Darifenacin ER tablets 15 mg and 7.5 mg • Cinacalcet tablets 90 mg, 60 mg and 30 mg • Ambrisentan tablets 10 mg and 5 mg • Valganciclovir tablets 450 mg • Ritonavir tablets USP 100 mg • Abacavir (sulfate)/Lamivudine Tablet 600mg/300mg • Efavirenz/Lamivudine/Tenofovir disoproxil fumarate Tablet 600mg/300mg/ 300mg Not all WHO products under PQ were specifically covered
MHRA, UK	Dates of inspection:	19 – 23 February 2018
	Type of inspection:	GMP inspection
	Block/Unit:	Unit I and Unit II
	Type of products/Dosage forms covered:	Tablets WHO products under PQ were not specifically covered
US FDA, USA	Dates of inspection:	27 November – 6 December 2017
	Type of inspection:	Surveillance inspection
	Block/Unit:	Unit I and Unit II
	Type of products/Dosage forms	• Abacavir Sulfate Tablets USP 300mg

	covered:	• Abacavir/Lamivudine Tablets USP 600/300mg • Darifenacin ER Tablets 7.5mg & 15mg • Ritonavir Tablets USP 100mg Not all WHO products under PQ were specifically covered
Part 3	**Summary of the last WHO inspection**	
Date and conclusion of most recent WHO inspection	The site (Unit I and II) was inspected by the WHO 19 to 25 January 2018. Initial conclusion "Based on the areas inspected, the people met and the documents reviewed, and considering the findings of the inspection, including the deficiencies listed in the Inspection Report, a decision on the compliance of Cipla Ltd located at Unit 1, Plot A-33, A-37/2/2 & A-2 MIDC Industrial Area, Patalganga, Raigad District, Maharashtra, 410 220, India and Unit II located at Plot A-42 MIDC Industrial Area, Patalganga, Raigad District, Maharashtra, 410 220, India with WHO GMP guidelines will be made after the manufacturer's response to the deficiencies has been assessed" CAPAs were submitted and assessed by the PQT: Inspection Team and the inspection, following the review of the CAPA, was closed 22 June 2018 as compliant with the standards of GMP published by WHO.	
Summary of manufacturing activities as of January 2018	Manufacturing, quality control and batch release of: Non-sterile medicinal products: coated/uncoated tablets, Active Pharmaceutical Ingredients (APIs) and drug intermediates	
General information about the company and manufacturing site as of January 2018	Cipla Limited is a public limited company established in 1935 by Dr K.A. Hamied and managed by a professional board of directors. It has its own management control & operation and has no parent company. Cipla manufactures products of various ranges including prescription, animal health care, OTC and APIs which are supplied to over 150 countries, located in the various regions including USA, Europe, Australia South America, Brazil, Middle East Asia and Africa. It also has Research located at Vikhroli, Patalganga and Bengaluru	
Focus of the last WHO inspection	The inspection covered sections of the WHO GMP Main Principles for non-sterile pharmaceutical products	
Areas inspected	Pharmaceutical quality system • Quality risk management • CC • Deviations • PQRs of o Darunavir Ethanoate Tablet 800mg o Artemether/Lumefantrine tablets 20mg/ 120mg o Abacavir Sulfate 300 mg tablets o Artesunate/Amodiaquine (as hydrochloride) tablets 100 mg/270 mg Good manufacturing practices for pharmaceutical products Sanitation and hygiene Qualification and validation • Validation master plan • Process validation • Cleaning validation	

	• Validation of computerized systems Complaints Product recalls Self-inspection and quality audits Personnel Training • QC analyst training Personal hygiene Premises • Ancillary areas • Storage areas • Weighing areas • Production areas • Quality control areas Equipment • Purified water • Compressed air • HVAC Materials • Starting materials • Packaging materials • Intermediate and bulk materials • Finished products • Rejected, recovered, reprocessed and reworked materials • Returned goods • Reagents and culture media • Reference materials • Waste materials Documentation • Labels • Specifications and testing procedure • Master formula • Batch processing records • Standard Operating Procedures and records Good practices in production • Processing areas • Packaging operations Good practices in quality control Control of starting materials, intermediate bulk and finished goods Out of specification (OOS) Test requirements for starting and packaging materials Finished products Batch record review Stability studies
Out of scope and restrictions (last WHO inspection)	Products out of scope of WHO PQ

WHO products covered by the last WHO inspection	Unit I 1. Artesunate and Amodiaquine as hydrochloride tablets 100mg/270mg 2. Artesunate and Amodiaquine as hydrochloride tablets 50/135mg 3. Artesunate and Amodiaquine as hydrochloride tablets 25mg/67.5m 4. Abacavir (as sulfate) dispersible tablets 60mg 5. Abacavir (as sulfate) tablets 300mg 6. Abacavir (as sulfate) and Lamivudine dispersible tablets 60mg/30mg 7. Artemether and Lumefantrine tablets 20mg/120mg 8. Moxifloxacin (as hydrochloride) tablets 400mg 2. Abacavir (as sulfate) and Lamivudine dispersible tablets 120mg/60mg 3. Isoniazid, Pyridoxine hydrochloride, Sulfamethoxazole & Trimethoprim tablets 300/25/800/ 160mg Unit II 1. Artesunate and Amodiaquine as hydrochloride tablets 100 mg/270mg 2. Artesunate and Amodiaquine as hydrochloride tablets 50mg/135mg 3. Artesunate and Amodiaquine as hydrochloride tablets 25mg/67.5mg 4. Abacavir (as sulfate) tablets 300mg 5. Abacavir (as sulfate) and Lamivudine dispersible tablets 60mg/30mg 6. Artemether and Lumefantrine tablets 20mg/120mg 7. Moxifloxacin (as hydrochloride) tablets 400mg 8. Nevirapine dispersible tablets 100 mg 9. Nevirapine dispersible tablets 50mg 10. Ofloxacin tablets 400mg 11. Ofloxacin tablets 200mg 12. Artesunate and Mefloquine (as hydrochloride) tablets 100/200mg 13. Artesunate and Mefloquine (as hydrochloride) tablets 25/50mg 14. Ethionamide tablets 250mg 15. Sofosbuvir tablets 400mg 16. Darunavir Ethanolate tablets 400mg 17. Darunavir Ethanolate tablets 600mg 18. Atazanavir (as sulfate)/Ritonavir tablets 300mg/100mg 19. Lamivudine and Tenofovir Disoproxil Fumarate tablets300mg/300mg 20. Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate tablets 600mg/300mg/300mg 21. Darunavir Ethanolate tablets 800mg 22. Isoniazid, Pyridoxine hydrochloride, Sulfamethoxazole & Trimethoprim tablets 300/25/800/ 160mg 23. Abacavir (as sulfate) and Lamivudine dispersible tablets 120mg/60mg
Additional products to be covered by this desk assessment:	Unit I 1. Abacavir (sulfate)/Lamivudine Tablet, Film-coated 600mg/300mg Unit II 1. Daclatasvir (dihydrochloride) Tablet, Film-coated 30mg 2. Daclatasvir (dihydrochloride) Tablet, Film-coated 60mg 3. Daclatasvir (dihydrochloride) + Sofosbuvir Tablet, Film-coated 60mg + 400mg 4. Ritonavir Tablet, Film-coated 25mg

Abbreviations	Meaning
AHU	Air handling unit
API	Active pharmaceutical ingredient
BMR	Batch manufacturing record
BPR	Batch packing record
CAPA	Corrective and preventive action
CC	Change control
CoA	Certificate of analysis
FPP	Finished pharmaceutical product
GMP	Good manufacturing practices
PQR	Product quality review
SMF	Site master file
SOP	Standard operating procedure

Part 4	Summary of the assessment of supporting documentation

a) List of all regulatory inspections performed in the last 5 years and their outcomes Unit I and Unit II:

	Authority	Dates of inspection	Outcome
1	World Health Organization (WHO), Geneva	19th - 25th January 2018	Approved
2	United States Food & Drug Administration (USFDA)	12th - 16th October 2015	EIR received
3	United States Food & Drug Administration (USFDA)	27th November - 06th December 2017	EIR Received
4	United States Food & Drug Administration (USFDA)	04th - 13th November 2019	EIR received
5	Medicine & Healthcare Product Regulatory Agency (MHRA), UK	19th - 23rd February 2018	Approved
6	Joint Inspection by Central Drugs Standard Control Organization (CDSCO) and Food & Drug Administration, Maharashtra, India - Unit I	06th – 07th April 2016	Approved
7	Joint Inspection by Central Drugs Standard Control Organization (CDSCO) and Food & Drug Administration, Maharashtra, India - Unit I	08th – 10th August 2018	Approved
8	Joint Inspection by Central Drugs Standard Control Organization (CDSCO) and Food & Drug Administration, Maharashtra, India - Unit II	19th – 20th September 2016 02nd February 2017	Approved
9	Joint Inspection by Central Drugs Standard Control Organization (CDSCO) and Food & Drug Administration, Maharashtra, India - Unit II	06th – 08th May 2019 26th August 2019	Approved
10	National Medicines & Poisons Board (NMPB), Sudan	28th – 30th October 2015	Approved
11	Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA),	20 – 24 August 2017	Approved

	Authority	Dates of inspection	Outcome
	Colombia		
12	National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria	12th December 2017	Approved
11	Pharmacy Board of Sierra Leone	29th October 2018	Compliance sent to authority on 26.06.2019
12	National Drug Authority (NDA), Uganda	29th - 30th November 2018	Approved
13	Pharmacy & Poisons Board (PPB), Kenya	2nd - 5th December 2015	Approved
14	Pharmacy & Poisons Board (PPB), Kenya	16th - 18th December 2019	Approved
15	Medicines Control Authority of Zimbabwe (MCAZ), Zimbabwe.	17th - 19th December 2015	Approved
Desk top Audits			
1	Therapeutic Goods Administration (TGA), Australia	August 2018	Approved
2	Agencia Nacional de Vigilancia Sanitaria (ANVISA), Brazil Note: Applicable to Unit I	June 2019	Approved
3	Medicines Control Authority of Zimbabwe (MCAZ), Zimbabwe.	July 2020	Approved

b) Manufacturing authorization granted by national authorities:
License No (25) 845 & (28) 707 valid until 31.12.2022 – Unit I
Form 26 - license No (25) KD620 & (28) KD 435 valid until 17.08.2021 – Unit II

c) Site master file:
SMF Unit I and Unit II and layouts submitted and reviewed. SMF written according to the WHO TRS No. 961, Annex 14

d) List of all the products and dosage forms manufactured on-site:
Unit I
Total 58 number of products are being manufactured of the following therapeutic groups: Antiretroviral, Antiviral, Antimalarial, Antidiabetic, Antihistaminic, NSAID, CNS Stimulant, Cardiovascular, Anti-Emetic and Antivertigo, Antiallergic, Antihypertensive, Anti-inflammatory, Antiepileptic, Pro-Kinetic, Antidiarrheal, Analgesic, Antipyretic, Expectorants/Cold preparations/Mucolytes, Anticold-Antiallergic, Haemorrhoelogic agent, Antibacterial, Antifungal, Nasal Decongestant, Anticoagulant, Hypnotics.

Unit II
Total 101 number of products are being manufactured of the following therapeutic groups: Antiretroviral, Antihypertensive, Antimalarial, Anti- Hyperlipoproteinemic, Antihistaminic, Antiosteoporotic, Antipsychotic, Calcimimetic agent, Antibacterial, Muscarinic Receptor, Antagonist, Antiviral, Anti-Inflammatory, Antidiabetic, Antispasmodic, Antifungal, Antiulcerant, Treatment of Hepatitis C, Anti – infective, Anti-hepatitis, Antiepileptic, Anti-coagulant and Antithrombotic agents

e) Most recent product quality reviews (PQR)s of the concerned WHO products:

Unit I

Submitted

1. Artemether/Lumefantrine Tablet 20mg/120 mg May 2019 – Apr 2020

Submitted and checked

1. Abacavir (sulfate)/Lamivudine Tablet USP 600mg/300mg Mar 2019 – Mar 2020
2. Abacavir Tablet 300 mg Dec 2018 – Nov 2019
3. Abacavir Dispersible Tablet 60 mg March 2019 – Mar 2020
4. Abacavir (sulfate)/Lamivudine Tablet, Dispersible 60mg/30mg May 2019 – May 2020

Submitted and reviewed

1. Abacavir (sulfate)/Lamivudine Tablet, Film-coated 600mg/300mg Mar 2019 – Feb 2020
2. Isoniazid/Pyridoxine hydrochloride/Sulfamethoxazole/Trimethoprim Tablet 300mg/25mg/800mg/160mg Sept 2018 – Aug 2019
3. Abacavir (as sulfate) and Lamivudine dispersible tablets 120mg/60mg Apr 2019- Apr. 2020

Not submitted – batches not executed

1. Amodiaquine (hydrochloride)/Artesunate Tablet 67.5mg/25mg
2. Amodiaquine (hydrochloride)/Artesunate Tablet 135mg/50mg
3. Amodiaquine (hydrochloride)/Artesunate Tablet 270mg/100mg

Unit II

Submitted

1. Nevirapine Tablet, Dispersible 50mg Nov 2018 – Oct 2019
2. Abacavir (sulfate)/Lamivudine Tablet, Dispersible 60mg/30mg Feb 2018 – Jan 2019
3. Artesunate/Mefloquine (hydrochloride) Tablet 25mg/50mg and Artesunate/Mefloquine (hydrochloride) Tablet 100mg/200mg Nov 2018 – Oct 2019

Submitted and checked

1. Lamivudine/Tenofovir disoproxil fumarate Tablet, Film-coated 300mg/300mg Mar 2018 – Feb 2019
2. Amodiaquine (hydrochloride)/Artesunate Tablet 67.5mg/25mg, Amodiaquine (hydrochloride)/Artesunate Tablet 135mg/50mg and Amodiaquine (hydrochloride)/Artesunate Tablet 270mg/100mg Apr 2018 – Mar 2019

Submitted and reviewed

1. Efavirenz/Lamivudine/Tenofovir disoproxil fumarate Tablet, Film-coated 600mg/300mg/300mg Nov 2017 – Oct 2018

Not submitted – not commercialized

1. Abacavir (sulfate) Tablet 300mg
2. Nevirapine Tablet, Dispersible l00 mg
3. Darunavir (Ethanolate) Tablet, Film-coated 400mg
4. Darunavir (Ethanol ate) Tablet, Film-coated 600mg
5. Atazanavir (sulfate)/Ritonavir Tablet, Film-coated 300mg/100mg
6. Isoniazid/Pyridoxine hydrochloride/ Sulfamethoxazole/ Trimethoprim Tablet 300mg/25mg/800mg/ l 60mg
7. Darunavir (Ethanolate) Tablet, Film-coated 800mg
8. Sofosbuvir Tablet, Film-coated 400mg

9. Daclatasvir (dihydrochloride) Tablet, Film-coated 30mg
10. Daclatasvir (dihydrochloride) Tablet, Film-coated 60mg
11. Daclatasvir (dihydrochloride) + Sofosbuvir Tablet, Film-coated 60mg + 400mg
12. Artemether/Lumefantrine Tablet 20mg/120mg
13. Ethionamide Tablet, Film-coated 250mg
14. Ofloxacin Tablet, Film-coated 200mg
15. Ofloxacin Tablet, Film-coated 400mg
16. Ritonavir Tablet, Film-coated 25mg

f) Batch manufacturing and packaging records, including the analytical part, for the most recently released batch of relevant products:

Unit I

Not submitted - not commercialized

1. Amodiaquine (hydrochloride)/Artesunate Tablet 67.5mg/25mg
2. Amodiaquine (hydrochloride)/Artesunate Tablet 135mg/50mg
3. Amodiaquine (hydrochloride)/Artesunate Tablet 270mg/100mg
4. Abacavir (sulfate)/Lamivudine Tablet film coated 600mg/300 mg

Not submitted not manufactured from 2017

1. Artemether/Lumefantrine Tablet 20mg/120 mg
2. Abacavir Dispersible Tablet 60 mg
3. Abacavir Tablet 300 mg

Submitted and checked

1. Abacavir (sulfate)/Lamivudine Tablet 600mg/300mg (ANDA 091144 USFDA)
2. Abacavir (sulfate)/Lamivudine Tablet, Dispersible 60mg/30mg)
3. Isoniazid/Pyridoxine hydrochloride/Sulfamethoxazole/Trimethoprim Tablet 300mg/25mg/800mg/160mg
4. Abacavir (as sulfate) and Lamivudine dispersible tablets 120mg/60mg
5. Abacavir (sulfate)/Lamivudine Tablet, Film-coated 600mg/300mg (HA743)

UNIT II

Not submitted – not commercialized

1. Abacavir (sulfate) Tablet 300mg
2. Nevirapine Tablet, Dispersible 100mg
3. Darunavir (Ethanolate) Tablet, Film-coated 400mg
4. Darunavir (Ethanolate) Tablet, Film-coated 600mg
5. Darunavir (Ethanolate) Tablet, Film-coated 800mg
6. Atazanavir (sulfate)/Ritonavir Tablet, Film-coated 300mg/100mg
7. Isoniazid/Pyridoxine hydrochloride/Sulfamethoxazole/Trimethoprim Tablet 300mg/25mg/800mg/160mg
8. Sofosbuvir Tablet, Film-coated 400mg
9. Daclatasvir (dihydrochloride) Tablet, Film-coated 30mg
10. Daclatasvir (dihydrochloride) Tablet, Film-coated 60mg
11. Daclatasvir (dihydrochloride) + Sofosbuvir Tablet, Film-coated 60mg + 400mg
12. Artemether/Lumefantrine Tablet 20mg/120mg
13. Ethionamide Tablet, Film-coated 250mg
14. Ofloxacin Tablet, Film-coated 200mg
15. Ofloxacin Tablet, Film-coated 400mg
16. Ritonavir Tablet, Film-coated 25mg

Submitted and checked

1. Artesunate/Mefloquine (hydrochloride) Tablet 25mg/50mg
2. Abacavir (sulfate)/Lamivudine Tablet, Dispersible 120mg/60mg
3. Lamivudine/Tenofovir disoproxil fumarate Tablet, Film-coated 300mg/300mg
4. Amodiaquine (hydrochloride)/Artesunate Tablet 67.5mg/25mg
5. Amodiaquine (hydrochloride)/Artesunate Tablet 135mg/50mg
6. Amodiaquine (hydrochloride)/Artesunate Tablet 270mg/100mg
7. Artesunate/Mefloquine (hydrochloride) Tablet 100mg/200mg

g) Master batch manufacturing and packaging records of the products of interest:

Unit I

Submitted

1. Abacavir (sulfate)/Lamivudine Tablet 600mg/300mg
2. Abacavir Tablet 300 mg
3. Abacavir Dispersible Tablet 60 mg
4. Abacavir (sulfate)/Lamivudine Tablet, Dispersible 60mg/30mg
5. Isoniazid/Pyridoxine hydrochloride/Sulfamethoxazole/Trimethoprim Tablet 300mg/25mg/800mg/160mg
6. Abacavir (as sulfate) and Lamivudine dispersible tablets 120mg/60mg
7. Artemether/Lumefantrine Tablet 20mg/120 mg
8. Abacavir (sulfate)/Lamivudine Tablet Film-coated 600mg/300mg

Not submitted – not commercialized

1. Amodiaquine (hydrochloride)/Artesunate Tablet 67.5mg/25mg
2. Amodiaquine (hydrochloride)/Artesunate Tablet 135mg/50mg
3. Amodiaquine (hydrochloride)/Artesunate Tablet 270mg/100mg

Unit II

Submitted

1. Nevirapine Tablet, Dispersible 50mg
2. Abacavir (sulfate)/Lamivudine Tablet, Dispersible 60mg/30mg
3. Efavirenz/Lamivudine/Tenofovir disoproxil fumarate Tablet, Film-coated 600mg/300mg/300mg
4. Abacavir (sulfate)/Lamivudine Tablet, Dispersible 120mg/60mg
5. Lamivudine/Tenofovir disoproxil fumarate Tablet, Film-coated 300mg/300mg
6. Artesunate/Mefloquine (hydrochloride) Tablet 25mg/50mg
7. Artesunate/Mefloquine (hydrochloride) Tablet 100mg/200mg
8. Amodiaquine (hydrochloride)/Artesunate Tablet 67.5mg/25mg
9. Amodiaquine (hydrochloride)/Artesunate Tablet 135mg/50mg
10. Amodiaquine (hydrochloride)/Artesunate Tablet 270mg/100mg

Not submitted – not commercialized

1. Abacavir (sulfate) Tablet 300mg
2. Nevirapine Tablet, Dispersible 100mg
3. Darunavir (Ethanolate) Tablet, Film-coated 400mg
4. Darunavir (Ethanolate) Tablet, Film-coated 600mg
5. Darunavir (Ethanolate) Tablet, Film-coated 800mg
6. Atazanavir (sulfate)/Ritonavir Tablet, Film-coated 300mg/100mg
7. Isoniazid/Pyridoxine hydrochloride/Sulfamethoxazole/Trimethoprim Tablet 300mg/25mg/800mg/160mg

8. Sofosbuvir Tablet, Film-coated 400mg
9. Daclatasvir (dihydrochloride) Tablet, Film-coated 30mg
10. Daclatasvir (dihydrochloride) Tablet, Film-coated 60mg
11. Daclatasvir (dihydrochloride) + Sofosbuvir Tablet, Film-coated 60mg + 400mg
12. Artemether/Lumefantrine Tablet 20mg/120mg
13. Ethionamide Tablet, Film-coated 250mg
14. Ofloxacin Tablet, Film-coated 200mg
15. Ofloxacin Tablet, Film-coated 400mg
16. Ritonavir Tablet, Film-coated 25mg

h) If any of the products are sterile, the completed batch records for the most recent media fill validation that is relevant to the product(s) of interest and report on its outcome:
N/A

i) Recalls in the past three years related to products with quality defects:

Recall No, class and type	Date	Market	Product and batch No	Reason for recall
Unit I				
CE18/09/02 Class II Voluntary	05.09.2018	South Africa	Roxxibid tablets 150 mg, PA61618	OOS for dissolution test, stability batch PA61618 at 18 M, storage condition 25 °C / 60 % RH
Unit II				
CE18/01/05 Class III Voluntary	19.01.2018	Uganda	Nifedipine slow released tablets 20 mg, PB50417	OOS results for dissolution and LOD test at 24 M storage condition 25 °C / 60 % RH
CE18/01/06 Class III Voluntary	19.01.2018	Madagascar	Nifedipine slow released tablets 20 mg, PB60162	OOS for dissolution test, stability testing at 12 M, storage condition 30 °C / 75 % RH
CE18/03/01 Class III Voluntary	06.03.2018	Madagascar	Nifedipine slow released tablets 20 mg, PB70424	OOS for dissolution test, stability testing at 6 M, storage condition 30 °C / 75 % RH
CE19/10/03 Class II Voluntary	17.10.2019	Yemen	Ultac 150 mg tablets PB90362, PB90365, PB90422, PB61504, PB61505	Notification received from Authority for presence of NDMA impurities in Ranitidine drug product considering adverse impact on patient safety
CE19/10/04 Class II Voluntary	18.10.2019	Trinidad Tobago	Ultac 150 mg tablets PB61502	Notification received from Authority for presence of NDMA impurities in Ranitidine drug product considering adverse impact on patient safety

j) Confirmation by the senior quality assurance representative that a full self-inspection or external audit dedicated to the products has been performed and all matters dealt with:
Confirmation submitted: that a full self-inspection or external audit dedicated to the products has been performed and all matters dealt with Unit I and Unit II

k) Copy of any warning letter, or equivalent regulatory action, issued by any authority to which the site provides or has applied to provide the product:
Confirmation submitted: No warning letter, or equivalent regulatory action, issued by any authority to Unit I and Unit II

k) Out-of-stock situations:
Confirmation submitted: no out of stock situations expected Unit I and Unit II

l) Additional documents submitted:
N/A

Part 5	Conclusion – Desk assessment outcome

Based on the previous WHO inspections and on the GMP evidence received and reviewed, it is considered that a desk assessment is acceptable in lieu of a WHO onsite inspection. The following sites:

- ***Cipla Ltd, Unit I (FPP)***, located at ***Plot A-33, A-37/2/2 & A-2 M.I.D.C., Patalganga, Taluka: Khalapur, District: Raigad Maharashtra state, 410 220, India***
- ***Cipla Ltd, Unit II (FPP),*** located at ***Plot A-42 M.I.D.C., Patalganga, Taluka: Khalapur, District: Raigad Maharashtra state, 410 220 India***

are considered to be operating at an acceptable level of compliance with WHO GMP guidelines.

This WHOPIR will remain valid for 3 years, provided that the outcome of any inspection conducted during this period is positive.

Part 6	List of guidelines referenced in this inspection report

1. WHO good manufacturing practices for pharmaceutical products: main principles. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-eighth Report Geneva, World Health Organization, 2014 (WHO Technical Report Series, No. 986), Annex 2. **Short name: WHO TRS No. 986, Annex 2**
http://www.who.int/medicines/areas/quality_safety/quality_assurance/expert_committee/trs_986/en/

2. WHO good manufacturing practices for active pharmaceutical ingredients. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth Report. Geneva, World Health Organization, 2010 (WHO Technical Report Series, No. 957), Annex 2. **Short name: WHO TRS No. 957, Annex 2**
http://www.who.int/medicines/publications/44threport/en/

3. WHO good manufacturing practices: water for pharmaceutical use. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fourth-sixth Report. Geneva, World Health Organization, 2012 (WHO Technical Report Series, No. 970), Annex 2.
Short name: WHO TRS No. 970, Annex 2
http://www.who.int/medicines/areas/quality_safety/quality_assurance/expert_committee/trs_970/en/

4. WHO guidelines for sampling of pharmaceutical products and related materials. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth Report. Geneva, World Health Organization, 2005 (WHO Technical Report Series, No. 929), Annex 4.
Short name: WHO TRS No. 929, Annex 4
http://whqlibdoc.who.int/trs/WHO_TRS_929_eng.pdf?ua=1

5. Guidelines on heating, ventilation and air-conditioning systems for non-sterile pharmaceutical products. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-second Report Geneva, World Health Organization, 2018 (WHO Technical Report Series, No. 1010), Annex 8. **Short name: WHO TRS No. 1010, Annex 8**
http://www.who.int/medicines/areas/quality_safety/quality_assurance/expert_committee/trs_1010/en/

6. Supplementary guidelines on good manufacturing practices: validation. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth Report. Geneva, World Health Organization, 2006 (WHO Technical Report Series, No. 937), Annex 4.
Short name: WHO TRS No. 937, Annex 4
http://whqlibdoc.who.int/trs/WHO_TRS_937_eng.pdf?ua=1

7. WHO Good Practices for Pharmaceutical Quality Control Laboratories. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth Report. Geneva, World Health Organization, 2010 (WHO Technical Report Series, No. 957, Annex 1.
Short name: WHO TRS No. 957, Annex 1
http://www.who.int/medicines/publications/44threport/en/

8. WHO Good Practices for Pharmaceutical Products Containing Hazardous Substances. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth Report. Geneva, World Health Organization, 2010 (WHO Technical Report Series, No. 957), Annex 3.
Short name: WHO TRS No. 957, Annex 3
http://www.who.int/medicines/publications/44threport/en/

9. WHO good manufacturing practices for sterile pharmaceutical products. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth Report Geneva, World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 6.
Short name: WHO TRS No. 961, Annex 6
http://whqlibdoc.who.int/trs/WHO_TRS_961_eng.pdf?ua=1

10. WHO guidelines on transfer of technology in pharmaceutical manufacturing WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth Report Geneva, World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 7.
Short name: WHO TRS No. 961, Annex 7
http://whqlibdoc.who.int/trs/WHO_TRS_961_eng.pdf?ua=1

11. Model guidance for the storage and transport of time-and temperature-sensitive pharmaceutical products. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth Report Geneva, World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 9. **Short name: WHO TRS No. 961, Annex 9**
http://whqlibdoc.who.int/trs/WHO_TRS_961_eng.pdf?ua=1

12. General guidelines for the establishment maintenance and distribution of chemical reference substances. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first Report Geneva, World Health Organization 2007 (WHO Technical Report Series, No.943) Annex 3. **Short name: WHO TRS No. 943, Annex 3**
http://whqlibdoc.who.int/trs/WHO_TRS_943_eng.pdf?ua=1

13. WHO good practices for pharmaceutical microbiology laboratories. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth Report Geneva, World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 2.
Short name: WHO TRS No. 961, Annex 2
http://whqlibdoc.who.int/trs/WHO_TRS_961_eng.pdf?ua=1

14. WHO guidelines on quality risk management. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-seventh Report Geneva, World Health Organization, 2013 (WHO Technical Report Series, No. 981), Annex 2. **Short name: WHO TRS No. 981, Annex 2**
http://www.who.int/medicines/areas/quality_safety/quality_assurance/expert_committee/trs_981/en/

15. WHO guidelines on variation to a prequalified product. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-seventh Report Geneva, World Health Organization, 2013 (WHO Technical Report Series, No. 981), Annex 3. **Short name: WHO TRS No. 981, Annex 3**
http://www.who.int/medicines/areas/quality_safety/quality_assurance/expert_committee/trs_981/en/

16. WHO guidelines for drafting a site master file. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth Report Geneva, World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 14. **Short name: WHO TRS No. 961, Annex 14**
http://whqlibdoc.who.int/trs/WHO_TRS_961_eng.pdf?ua=1

17. WHO Guidelines on good manufacturing practices: validation, Appendix 7: non-sterile process validation. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-ninth Report Geneva, World Health Organization, 2015 (WHO Technical Report Series, No. 992), Annex 3.
Short name: WHO TRS No. 992, Annex 3
http://www.who.int/medicines/areas/quality_safety/quality_assurance/expert_committee/WHO_TRS_992_web.pdf

18. WHO General guidance on hold-time studies WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-ninth Report Geneva, World Health Organization, 2015 (WHO Technical Report Series, No. 992), Annex 4. **Short name: WHO TRS No. 992, Annex 4**
http://www.who.int/medicines/areas/quality_safety/quality_assurance/expert_committee/WHO_TRS_992_web.pdf

19. WHO Technical supplements to Model Guidance for storage and transport of time – and temperature – sensitive pharmaceutical products. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-ninth Report Geneva, World Health Organization, 2015 (WHO Technical Report Series, No. 992), Annex 5. **Short name: WHO TRS No. 992, Annex 5**
http://www.who.int/medicines/areas/quality_safety/quality_assurance/expert_committee/WHO_TRS_992_web.pdf

20. Guidance on good data and record management practices. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fiftieth Report Geneva, World Health Organization, 2016 (WHO Technical Report Series, No. 996), Annex 5.
Short name: WHO GDRMP guidance or **WHO TRS No. 996, Annex 5**
http://www.who.int/medicines/publications/pharmprep/WHO_TRS_996_annex05.pdf

21. WHO general guidance on variations to multisource pharmaceutical products. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fiftieth Report Geneva, World Health Organization, 2016 (WHO Technical Report Series, No. 996), Annex 10.
Short name: WHO Multisource guidance or **WHO TRS No. 996, Annex 10**
http://www.who.int/medicines/publications/pharmprep/WHO_TRS_996_annex10.pdf

22. Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-second Report Geneva, World Health Organization, 2018 (WHO Technical Report Series, No. 1010), Annex 10.
Short name: WHO TRS No. 1010, Annex 10
http://www.who.int/medicines/publications/pharmprep/WHO_TRS_996_annex10.pdf

23. Production of water for injection by means other than distillation. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-fourth Report. Geneva, World Health Organization, 2020 (WHO Technical Report Series, No. 1025), Annex 3.
Short name: WHO TRS No. 1025, Annex 3
https://www.who.int/publications-detail/978-92-4-000182-4

24. Good chromatography practice. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-fourth Report. Geneva, World Health Organization, 2020 (WHO Technical Report Series, No. 1025), Annex 4.
Short name: WHO TRS No. 1025, Annex 4
https://www.who.int/publications-detail/978-92-4-000182-4

25. Points to consider for manufacturers and inspectors: environmental aspects of manufacturing for the prevention of antimicrobial resistance. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-fourth Report. Geneva, World Health Organization, 2020 (WHO Technical Report Series, No. 1025), Annex 6.
Short name: WHO TRS No. 1025, Annex 6
https://www.who.int/publications-detail/978-92-4-000182-4

26. WHO guidance on good practices for desk assessment of compliance with good manufacturing practices, good laboratory practices and good clinical practices for medical products regulatory decisions. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-second Report. Geneva, World Health Organization, 2018 (WHO Technical Report Series, No. 1010), Annex 9.
Short name: WHO TRS 1010, Annex 9
https://www.who.int/medicines/areas/quality_safety/quality_assurance/TRS1010annex9.pdf?ua=1